Boston Scientific (BSX) Stock Looks Cheap On Earnings While Returns Stay Weak

Boston Scientific stock has fallen sharply over the past year, yet the broader valuation checks still lean cheap, which sets up a clear tension between weak recent returns and what the fundamentals-based multiples are suggesting about value.

• Over the past 12 months, Boston Scientific shares are down 58.8%, which means the current price is reflecting a heavy reset in market expectations.
• Strong revenue and earnings growth, alongside insider buying, can support the case that current earnings and cash flow expectations remain too low, while slower adoption in key product areas and a reset in growth expectations may limit how much investors are willing to pay for the stock.
• On Simply Wall St's broader valuation checks, Boston Scientific screens as undervalued in 5 out of 6 areas, which points to a market price that is low relative to its fundamentals on several metrics.

For investors, the debate is whether Boston Scientific's steep share price decline has already incorporated the main risks, or if the current discount still overestimates the pressure on its long term earnings power.

Find out why Boston Scientific's -58.8% return over the last year is lagging behind its peers.

Is Boston Scientific a Bargain on Earnings?

The P/E ratio is a natural fit for Boston Scientific because earnings are central to how investors are judging its reset growth outlook.

On this yardstick, Boston Scientific trades on about 17.8x earnings, which is below both the Medical Equipment industry average of roughly 26.2x and a peer group average near 33.4x. A tailored fair P/E ratio that accounts for Boston Scientific's growth profile, margins, size and risks is estimated at about 30.5x, suggesting the current earnings multiple embeds a discount relative to what these fundamentals might justify.

Despite the cut to 2026 guidance and the sharp share price decline that followed, the P/E still values Boston Scientific at a clear discount to peers and to the modelled fair multiple. The gap between roughly 17.8x today and a fair level near 30.5x indicates that the market is assigning a cautious earnings outlook that may be harsher than the company's long term earnings record and balance sheet would imply.

On the P/E test, Boston Scientific stock appears undervalued relative to both its industry and its own modelled fair multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Boston Scientific Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Boston Scientific pick up where the valuation puzzle leaves off by spelling out what combination of future growth, margins and earnings would need to play out for the stock to be worth materially more or less than it is today on the Community page. Instead of stopping at a single output from a ratio or model, they describe the future that number rests on so you can judge and monitor whether those assumptions still look realistic.

One of the top community narratives on Boston Scientific: 57% undervalued

"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons..."

Read one of the top narratives on Boston Scientific

Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!

The Bottom Line

For Boston Scientific, the market-multiple view points to an undervalued stock, with its current P/E sitting well below both industry peers and a tailored fair ratio that factors in its profile. That gap reflects investor caution about how much growth and adoption Boston Scientific can sustain from here, rather than any single red flag in the fundamentals checks. What matters now is whether earnings delivery and execution in key product areas are strong enough to shift sentiment and narrow that discount, or whether the current valuation simply proves to be fair compensation for the ongoing growth and adoption risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com